194 related articles for article (PubMed ID: 7002102)
21. Overview of the role of angiotensin inhibitors in delineating the function of the renin-angiotensin system.
McCaa RE
Prog Biochem Pharmacol; 1980; 17():29-35. PubMed ID: 7010367
[TBL] [Abstract][Full Text] [Related]
22. Renin-angiotensin system and renal excretory function under conditions of hypovolemia and limited sodium intake.
Piryova B; Ikonomov O; Stoynev A; Natcheff N
Acta Physiol Pharmacol Bulg; 1986; 12(2):21-6. PubMed ID: 3532691
[TBL] [Abstract][Full Text] [Related]
23. [Effect of captopril in essential hypertension (author's transl)].
Mimran A; Targhetta R; Laroche B
Nouv Presse Med; 1981 Apr; 10(19):1579-82. PubMed ID: 7025849
[TBL] [Abstract][Full Text] [Related]
24. Effect of captopril on the systemic and renal responses to acute isotonic volume expansion in normal man.
Mimran A; Ribstein J
Proc Eur Dial Transplant Assoc; 1981; 18():603-7. PubMed ID: 7036174
[TBL] [Abstract][Full Text] [Related]
25. Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats.
Antonaccio MJ; Rubin B; Horovitz ZP; Laffan RJ; Goldberg ME; High JP; Harris DN; Zaidi I
Jpn J Pharmacol; 1979 Apr; 29(2):285-94. PubMed ID: 231700
[TBL] [Abstract][Full Text] [Related]
26. [Long term treatment of resistant hypertension with captopril (author's transl)].
Guedon J; Chaignon M; Lucsko M; Cuche JL; Aubert P; Piete AM
Nouv Presse Med; 1981 Apr; 10(19):1565-9. PubMed ID: 7025846
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacological effects of captopril].
Rubin B; Antonaccio J
Nouv Presse Med; 1981 Apr; 10(19):1531-46. PubMed ID: 6269555
[No Abstract] [Full Text] [Related]
28. Mechanism of the response to captopril in glucocorticoid hypertension.
Elijovich F; Krakoff LR
Clin Exp Hypertens A; 1982; 4(9-10):1795-814. PubMed ID: 6291817
[TBL] [Abstract][Full Text] [Related]
29. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of the acute effect of a converting enzyme inhibitor, captopril, in normal and hypertensive subjects].
Mimran A; Laroche B; Targhetta R; Roumieux JL
Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():61-5. PubMed ID: 6794529
[TBL] [Abstract][Full Text] [Related]
31. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.
Atlas SA; Case DB; Sealey JE; Laragh JH; McKinstry DN
Hypertension; 1979; 1(3):274-80. PubMed ID: 399239
[No Abstract] [Full Text] [Related]
32. A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats.
Takata Y; Di Nicolantonio R; Hutchinson JS
Clin Exp Pharmacol Physiol Suppl; 1982; 7():129-34. PubMed ID: 6183035
[TBL] [Abstract][Full Text] [Related]
33. Insulin-exacerbated hypertension in captopril-treated spontaneously hypertensive rats: role of sympathoexcitation.
Roysommuti S; Mozaffari MS; Wyss JM
Can J Physiol Pharmacol; 2003 Nov; 81(11):1036-41. PubMed ID: 14719038
[TBL] [Abstract][Full Text] [Related]
34. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat.
Marks ES; Bing RF; Thurston H; Swales JD
Clin Sci (Lond); 1980 Jan; 58(1):1-6. PubMed ID: 6986224
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the immediate hemodynamic effects of SQ 14225 (Captopril) and [Sar1, Ileu8] angiotensin II in patients with dialysis resistant hypertension.
Iseki K; Onoyama K; Fujimi S; Fukiyama K; Omae T
Clin Nephrol; 1982 Mar; 17(3):149-54. PubMed ID: 7039897
[TBL] [Abstract][Full Text] [Related]
36. SA446, a new orally active converting enzyme inhibitor: antihypertensive action and comparison with captopril in stroke-prone spontaneously hypersensitive rats.
Unger T; Yukimura T; Marin-Grez M; Lang RE; Rascher W; Ganten D
Eur J Pharmacol; 1982 Mar; 78(4):411-20. PubMed ID: 6281036
[TBL] [Abstract][Full Text] [Related]
37. Impaired baroreflex sensitivity and responses to angiotensin converting enzyme inhibitor in salt-induced hypertension and its prevention by dietary calcium supplement in Sprague-Dawley rats.
Ladipo CO; Egbe PE; Ibu JO
Afr J Med Med Sci; 2006 Mar; 35(1):29-36. PubMed ID: 17209324
[TBL] [Abstract][Full Text] [Related]
38. Effect of the angiotensin converting enzyme inhibitor, captopril (SQ14,225), on orthostatic sodium and water retention in patients with idiopathic edema.
Suzuki H; Fujimaki M; Nakane H; Saito I; Takeshita E; Saruta T
Nephron; 1985; 39(3):244-9. PubMed ID: 2983253
[TBL] [Abstract][Full Text] [Related]
39. [Treatment with captopril of idiopathic edemas (author's transl)].
Mimran A
Nouv Presse Med; 1981 Apr; 10(19):1594-5. PubMed ID: 7025852
[TBL] [Abstract][Full Text] [Related]
40. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.
Kohzuki M; Yasujima M; Kanazawa M; Yoshida K; Fu LP; Obara K; Saito T; Abe K
J Hypertens; 1995 Jan; 13(1):97-103. PubMed ID: 7759858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
